New Resistance Technologies and Interpretations Session Posters

A fuzzy relational system trained by genetic algorithms and HIV-1 resistance genotypes/virological response data from prospective studies usefully predicts treatment outcomes
M Prosperi

Application of multiple linear regression modelling to the quantitative prediction of HIV-1 drug susceptibility phenotype from viral genotype
H Vermeiren

Previous drug exposure data significantly increase the accuracy of artificial neural networks in predicting virological response to combination therapy
BA Larder

Probabilistic graphical models for prediction of HIV-1 drug resistance mutations based on antiretroviral treatment history
RW Shafer

Computing the genetic barrier
N Beerenwinkel

Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors are subtype dependent
J Snoeck

Evaluation of different approaches for the definition of clinically relevant breakpoints for phenotypic resistance data
B Winters

Comparison of original and updated genotypic and phenotypic susceptibility algorithms for treatment-experienced patients
D Kuritzkes

A genotypic inhibitory quotient (GIQ) for fosamprenavir/rtv (908/r)
R Elston

Experts select different antiretroviral drug regimens when presented with resistance data in the form of genotype, phenotype, or combined genotype plus phenotype
AR Zolopa

Genotypic algorithms specific to lopinavir/ritonavir outperform nonspecific lists of PI mutations in predicting virological response to lopinavir/ritonavir in PI-experienced patients
M Norton

d4T virtual phenotype can predict virological response to d4T monotherapy after AZT treatment, but not at the current cutoff
NS Shulman

Genotypic predictors of a response to didanosine monotherapy in zidovudine-experienced patients
J Delgado

An additive/substractive genotypic score as a determinant of the virological response to didanosine (ddI)-containing regimens in NRTI-experienced patients
B Masquelier

Comparison of HIV-1 viral load and resistance genotyping between frozen plasma and a novel dried plasma transportation matrix
RM Lloyd Jr

Development of a DNA microarray to detect HCV and HIV drug resistance
M Kozal

Performance of a commercial genotyping system for analysis of diverse HIV-1 strains
N Marlowe

A proposed approach to proficiency testing for HIV-1 drug resistance genotyping
JW Bremer

Repeated control assessments for resistance genotyping improve performances of laboratories
D Costagliola

Detection and characterization of rare drug resistant HIV-1 RT variants using a sensitive phenotypic assay
DV Nissley

Tropism determination and performance of phenoscript. HIV-1 entry inhibitor assay
JL Faudon

Simultaneously assessing association among baseline factors and time to virological failure and off-track in ACTG 398
G DiRienzo

Development of a tipranavir mutation score: analysis of protease mutations associated with phenotypic drug susceptibility and antiviral response in Phase II clinical trials
VM Kohlbrenner

Sensitivity of phenotypic analyses for detection of K65R or M184V in mixtures with wild-type HIV-1
ER Lanier

Characterization of nevirapine resistance mutations using RT-PCR and DNA sequencing methods in a mother-infant cohort following single dose nevirapine
S Loubser

New genotypic score comprising mutations impacting negatively and positively the virological response to didanosine in treatment-experienced patients from the randomized didanosine add on Jaguar study
AG Marcelin

Changes in genotypic resistance patterns for SQV, LPV and APV with rising phenotypic cut-off levels: analysis of TORO 1/2 database
K Tsai

Development of a new genotypic resistance assay involving the entire gp41 sequence for evaluating resistance to enfuvirtide
SL Walmsley